We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
+55.36%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$750M
AUM Growth
+$187M
(+33%)
Cap. Flow
+$114M
Cap. Flow
% of AUM
15.17%
Top 10 Holdings %
Top 10 Hldgs %
73.32%
Holding
52
New
16
Increased
12
Reduced
5
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$28.5M |
| 2 |
Ironwood Pharmaceuticals
IRWD
|
+$28M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$22M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$17.9M |
| 5 |
Kura Oncology
KURA
|
+$16.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$29.5M |
| 2 |
SGMO
SANGAMO THERAPEUTICS INC
SGMO
|
+$25.9M |
| 3 |
Editas Medicine
EDIT
|
+$12M |
| 4 |
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
|
+$4.52M |
| 5 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$3.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.33% |
| 2 | Miscellaneous | 2.67% |
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q3 2017 Portfolio in Review
As of Q3 2017, EcoR1 Capital held 52 positions worth $750M, up 33% from $563M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
EcoR1 Capital deployed $114M of net new capital in Q3 2017, opening 16 new positions and adding to 12 existing holdings. Its largest new stake was Immunomedics Inc: 2,860,019 shares worth $40M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 77% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $29.5M trimmed.
- EcoR1 Capital's largest Q3 2017 buy was Immunomedics Inc: 2,860,019 shares worth $40M.
- EcoR1 Capital added most to Ironwood Pharmaceuticals in Q3 2017, an estimated $28M increase.
- EcoR1 Capital's biggest Q3 2017 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $29.5M.
- EcoR1 Capital fully exited Editas Medicine in Q3 2017, selling an estimated $12M.
- EcoR1 Capital's ten largest holdings make up 73% of its $750M portfolio in Q3 2017.
- EcoR1 Capital opened 16 new positions and closed 13 in Q3 2017.
- EcoR1 Capital's portfolio value rose 33% quarter-over-quarter to $750M.
Based on EcoR1 Capital's 13F filing for Q3 2017, filed 14 Nov 2017.